250 related articles for article (PubMed ID: 19812297)
1. Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus.
Faerch M; Christensen JH; Rittig S; Johansson JO; Gregersen N; de Zegher F; Corydon TJ
Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1518-25. PubMed ID: 19812297
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
[TBL] [Abstract][Full Text] [Related]
3. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
4. Partial nephrogenic diabetes insipidus caused by a novel mutation in the AVPR2 gene.
Faerch M; Christensen JH; Corydon TJ; Kamperis K; de Zegher F; Gregersen N; Robertson GL; Rittig S
Clin Endocrinol (Oxf); 2008 Mar; 68(3):395-403. PubMed ID: 17941907
[TBL] [Abstract][Full Text] [Related]
5. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
Robben JH; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
[TBL] [Abstract][Full Text] [Related]
6. An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system.
Birnbaumer M; Gilbert S; Rosenthal W
Mol Endocrinol; 1994 Jul; 8(7):886-94. PubMed ID: 7984150
[TBL] [Abstract][Full Text] [Related]
7. V2R mutations and nephrogenic diabetes insipidus.
Bichet DG
Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
Oksche A; Schülein R; Rutz C; Liebenhoff U; Dickson J; Müller H; Birnbaumer M; Rosenthal W
Mol Pharmacol; 1996 Oct; 50(4):820-8. PubMed ID: 8863826
[TBL] [Abstract][Full Text] [Related]
9. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes.
Sadeghi H; Robertson GL; Bichet DG; Innamorati G; Birnbaumer M
Mol Endocrinol; 1997 Nov; 11(12):1806-13. PubMed ID: 9369448
[TBL] [Abstract][Full Text] [Related]
10. Cellular and subcellular distribution of the type-2 vasopressin receptor in the kidney.
Fenton RA; Brønd L; Nielsen S; Praetorius J
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F748-60. PubMed ID: 17553938
[TBL] [Abstract][Full Text] [Related]
11. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
Los EL; Deen PM; Robben JH
J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature.
Neocleous V; Skordis N; Shammas C; Efstathiou E; Mastroyiannopoulos NP; Phylactou LA
Metabolism; 2012 Jul; 61(7):922-30. PubMed ID: 22386940
[TBL] [Abstract][Full Text] [Related]
13. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
[TBL] [Abstract][Full Text] [Related]
14. [From genes to disease: from vasopressin-V2-receptor and aquaporine-2 to nephrogenic diabetes insipidus].
Knoers NV; Deen PM
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2402-4. PubMed ID: 11145096
[TBL] [Abstract][Full Text] [Related]
15. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
16. Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus.
Tsukaguchi H; Matsubara H; Taketani S; Mori Y; Seido T; Inada M
J Clin Invest; 1995 Oct; 96(4):2043-50. PubMed ID: 7560098
[TBL] [Abstract][Full Text] [Related]
17. Vasopressin receptor mutations causing nephrogenic diabetes insipidus.
Bichet DG; Turner M; Morin D
Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088
[TBL] [Abstract][Full Text] [Related]
18. Effect of the cGMP pathway on AQP2 expression and translocation: potential implications for nephrogenic diabetes insipidus.
Boone M; Kortenoeven M; Robben JH; Deen PM
Nephrol Dial Transplant; 2010 Jan; 25(1):48-54. PubMed ID: 19666909
[TBL] [Abstract][Full Text] [Related]
19. Misfolded vasopressin V2 receptors caused by extracellular point mutations entail congential nephrogenic diabetes insipidus.
Postina R; Ufer E; Pfeiffer R; Knoers NV; Fahrenholz F
Mol Cell Endocrinol; 2000 Jun; 164(1-2):31-9. PubMed ID: 11026555
[TBL] [Abstract][Full Text] [Related]
20. A low-affinity vasopressin V2-receptor gene in a kindred with X-linked nephrogenic diabetes insipidus.
Yokoyama K; Yamauchi A; Izumi M; Itoh T; Ando A; Imai E; Kamada T; Ueda N
J Am Soc Nephrol; 1996 Mar; 7(3):410-4. PubMed ID: 8704106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
